← All trials
NCT04958434
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 11, 2021
- Primary completion
- Jul 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- Jul 12, 2021
- Last posted
- Nov 3, 2021
- Enrollment
- 55
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Transcenta TherapeuticsLead sponsor
- Transcenta TherapeuticsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.